利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.048 秒)

    Regulated nucleic acids in pathogenesis of Alzheimer's Disease
    1.
    发明申请
    Regulated nucleic acids in pathogenesis of Alzheimer's Disease 审中-公开
    调节核酸在阿尔茨海默氏病的发病机制中

    公开(公告)号：US20050176030A1

    公开(公告)日：2005-08-11

    申请号：US10973858

    申请日：2004-10-25

    申请人： Li Gan ,  Mirella Gonzalez-Zulueta ,  Shiming Ye ,  Roman Urfer ,  Karoly Nikolich

    发明人： Li Gan ,  Mirella Gonzalez-Zulueta ,  Shiming Ye ,  Roman Urfer ,  Karoly Nikolich

    IPC分类号： C12Q1/68 ,  G01N33/53 ,  G01N33/567

    CPC分类号： C12Q1/6883 ,  C12Q2600/142 ,  C12Q2600/158

    摘要： This invention provides a method for detecting a neurodegenerative disorder or susceptibility to a neurodegenerative disorder in a subject. This invention also provides a method of developing a modulator of an Alzheimer's Disease-associated gene or protein. Also included in the present invention is a method reducing toxic Aβ peptide production by a eukaryotic cell, a method of ameliorating neurotoxicity of Aβ peptide. The present invention further embodies compositions such as Alzheimer's Disease-associated genes, the polypeptides encoded therefrom, gene delivery vehicles, host cells and kits comprising the Alzheimer's Disease-associated genes and/or polypeptides.

    摘要翻译： 本发明提供了一种用于检测受试者中神经变性疾病或对神经变性疾病的易感性的方法。 本发明还提供了开发阿尔茨海默病相关基因或蛋白质的调节剂的方法。 本发明还包括减少真核细胞产生毒性的Aβ肽的方法，改善Abeta肽的神经毒性的方法。 本发明进一步体现了诸如阿尔茨海默病相关基因，由其编码的多肽，基因递送载体，宿主细胞和包含阿尔茨海默病相关基因和/或多肽的试剂盒的组合物。

    Sigma ligands for neuronal regeneration and functional recovery
    3.
    发明申请
    Sigma ligands for neuronal regeneration and functional recovery 审中-公开
    Sigma配体用于神经元再生和功能恢复

    公开(公告)号：US20050020483A1

    公开(公告)日：2005-01-27

    申请号：US10868048

    申请日：2004-06-14

    申请人： Donna Oksenberg ,  Mattias Rickhag ,  Mehrdad Shamloo ,  Karoly Nikolich ,  Roman Urfer ,  Tadeusz Wieloch

    发明人： Donna Oksenberg ,  Mattias Rickhag ,  Mehrdad Shamloo ,  Karoly Nikolich ,  Roman Urfer ,  Tadeusz Wieloch

    IPC分类号： A61K31/00 ,  A61K31/195 ,  A61K31/438 ,  A61K31/473 ,  A61K31/485 ,  A61K31/495 ,  A61K38/17 ,  C07D295/096 ,  G06F21/00 ,  H04L29/06

    CPC分类号： C07D295/096 ,  A61K31/00 ,  A61K31/438 ,  A61K31/495

    摘要： The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptors. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.

    摘要翻译： 本发明公开了用于促进神经退行性疾病中的神经元再生和功能恢复的方法和组合物。 该方法和组合物利用了σ受体的配体。 这些分子可以单独递送或与治疗或预防神经变性疾病如由缺血性卒中，糖尿病性周围神经病变，癌症治疗诱发的神经病变，多发性硬化，肌萎缩性侧索硬化，创伤性脑损伤，脊髓损伤，亨廷顿舞蹈症 疾病或帕金森病。 在其他方法中，σ受体配体在中风后施用以促进功能恢复。 σ受体配体的施用使功能恢复更快。

    Sigma ligands for neuronal regeneration and functional recovery
    4.
    发明申请
    Sigma ligands for neuronal regeneration and functional recovery 审中-公开
    Sigma配体用于神经元再生和功能恢复

    公开(公告)号：US20110152284A1

    公开(公告)日：2011-06-23

    申请号：US12656182

    申请日：2010-01-20

    申请人： Tadeusz Wieloch ,  Donna Oksenberg ,  Roman Urfer

    发明人： Tadeusz Wieloch ,  Donna Oksenberg ,  Roman Urfer

    IPC分类号： A61K31/495 ,  A61K31/438 ,  A61P25/16 ,  A61P25/28

    CPC分类号： A61K31/495 ,  A61K9/2018 ,  A61K31/485

    摘要： The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferable AGY-94806, or salts or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, Huntington's disease, or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects functional recovery.

    摘要翻译： 本发明公开了用于促进神经退行性疾病中的神经元再生和功能恢复的方法和组合物。 所述方法和组合物利用了σ受体的配体，其中配体优选为AGY-94806，或其盐或溶剂化物。 这些分子可以单独或与治​​疗或预防神经变性疾病如由缺血性卒中，多发性硬化，肌萎缩性侧索硬化，创伤性脑损伤，亨廷顿病或帕金森病引起的疾病的药物组合递送。 在其他方法中，σ受体配体在中风后施用以促进功能恢复。 σ受体配体的施用会影响功能恢复。

    Sigma ligands for neuronal regeneration and functional recovery
    6.
    发明申请
    Sigma ligands for neuronal regeneration and functional recovery 审中-公开
    Sigma配体用于神经元再生和功能恢复

    公开(公告)号：US20060052386A1

    公开(公告)日：2006-03-09

    申请号：US11264957

    申请日：2005-11-01

    申请人： Tadeusz Wieloch ,  Donna Oksenberg ,  Roman Urfer

    发明人： Tadeusz Wieloch ,  Donna Oksenberg ,  Roman Urfer

    IPC分类号： A61K31/495

    CPC分类号： A61K31/495 ,  A61K9/2018 ,  A61K31/485

    摘要： The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.

    摘要翻译： 本发明公开了用于促进神经退行性疾病中的神经元再生和功能恢复的方法和组合物。 所述方法和组合物利用了σ受体的配体，其中配体优选为AGY-94806，或其盐或溶剂化物。 这些分子可以单独递送或与治疗或预防神经变性疾病如由缺血性卒中，糖尿病性周围神经病变，癌症治疗诱发的神经病变，多发性硬化，肌萎缩性侧索硬化，创伤性脑损伤，脊髓损伤，亨廷顿舞蹈症 疾病或帕金森病。 在其他方法中，σ受体配体在中风后施用以促进功能恢复。 σ受体配体的施用使功能恢复更快。

    METHODS AND COMPOSITIONS FOR THE PROTECTION OF SENSORY CELLS
    9.
    发明申请
    METHODS AND COMPOSITIONS FOR THE PROTECTION OF SENSORY CELLS 审中-公开
    用于保护感染细胞的方法和组合物

    公开(公告)号：US20170072015A1

    公开(公告)日：2017-03-16

    申请号：US15123238

    申请日：2015-03-03

    申请人： Lawrence M. Schwartz ,  Gerald Commissiong ,  David A. Lowe ,  Roman Urfer

    发明人： Lawrence M. Schwartz ,  Gerald Commissiong ,  David A. Lowe ,  Roman Urfer

    IPC分类号： A61K38/18

    CPC分类号： A61K38/185

    摘要： Disclosed herein are methods of treating or preventing cell death-related sensory cell loss in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject. Also disclosed are methods of treating or preventing drug-induced ototoxicity in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject.

    摘要翻译： 本文公开了在有需要的受试者中治疗或预防细胞死亡相关的感觉细胞损失的方法，所述方法包括给受试者施用有效量的一种或多种神经保护肽。 还公开了在有需要的受试者中治疗或预防药物诱导的耳毒性的方法，所述方法包括向受试者施用有效量的一种或多种神经保护肽。

    Treatment methods using NGF variants
    10.
    发明授权
    Treatment methods using NGF variants 有权
    使用NGF变体的治疗方法

    公开(公告)号：US08101571B2

    公开(公告)日：2012-01-24

    申请号：US12254458

    申请日：2008-10-20

    申请人： Leonard G. Presta ,  Roman Urfer ,  John W. Winslow

    发明人： Leonard G. Presta ,  Roman Urfer ,  John W. Winslow

    IPC分类号： A61K38/18

    CPC分类号： C07K14/48 ,  A61K38/00

    摘要： NGF variants which have trkC-binding activity and trkC-signal inducing activity are provided. The variants optionally have trkA or trkB binding and signal induction activity. The NGF variants of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the NGF variant neurotrophins are also provided.

    摘要翻译： 提供具有trkC结合活性和trkC信号诱导活性的NGF变体。 变体任选具有trkA或trkB结合和信号诱导活性。 本发明的NGF变体可用于治疗神经元疾病。 还提供了编码NGF变体神经营养蛋白的核酸和表达载体。